In a post hoc analysis of the phase 3b SEQUENCE trial in anti-TNF-refractory Crohn's disease patients on corticosteroids at baseline, risankizumab beat ustekinumab on corticosteroid-free clinical remission (CDAI) by 25.4% at week 48 and endoscopic remission by 20.2%.
Secondary analysis
Raine et al. Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial